Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Vito Amoroso, Fausto Petrelli, Rebecca Pedersini, Edda Lucia Simoncini, Philippe Clézardin, Sandro Barni & Alfredo Berruti. (2015) Adjuvant Bisphosphonates in Patients with Breast Cancer: Does the Potency Matter?. Future Oncology 11:21, pages 2853-2856.
Read now
Read now
Seung Sang Ko & V Craig Jordan. (2011) Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opinion on Pharmacotherapy 12:4, pages 657-674.
Read now
Read now
Theresa A. Guise, Adam Brufsky & Robert E. Coleman. (2010) Understanding and Optimizing Bone Health in Breast Cancer. Current Medical Research and Opinion 26:sup3, pages 3-20.
Read now
Read now
Henning T Mouridsen, Per Lønning, Matthias W Beckmann, Kimberly Blackwell, Julie Doughty, Joseph Gligorov, Antonio Llombart-Cussac, Andre Robidoux, Beat Thürlimann & Michael Gnant. (2010) Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy 10:11, pages 1825-1836.
Read now
Read now
Onder Tonyali, Cagatay Arslan & Kadri Altundag. (2010) The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives. Expert Opinion on Pharmacotherapy 11:16, pages 2715-2725.
Read now
Read now
Matti S. Aapro. (2010) Challenges in Clinical Patient Management. Cancer Investigation 28:sup1, pages 14-27.
Read now
Read now
Francesco Bertoldo, Serena Pancheri, Sonia Zenari & Stefania Boldini. (2010) Emerging drugs for the management of cancer treatment induced bone loss. Expert Opinion on Emerging Drugs 15:2, pages 323-342.
Read now
Read now
Michaela J Higgins & Ben H Park. (2009) Expanding role of bisphosphonates in the management of early breast cancer. Expert Review of Anticancer Therapy 9:8, pages 1051-1054.
Read now
Read now
Susanne Møller, Maj-Britt Jensen, Bent Ejlertsen, Karsten D. Bjerre, Martin Larsen, Hanne B. Hansen, Peer Christiansen & Henning T. Mouridsen. (2008) The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncologica 47:4, pages 506-524.
Read now
Read now
Articles from other publishers (54)
Praful Pandey, Aparna Sharma & Ajay Gogia. (2023) Bone health in breast cancer. Current Problems in Cancer 47:3, pages 100959.
Crossref
Crossref
Zohreh Sanaat, Ozra Nouri, Monireh Khanzadeh, Hadi Mostafaei, Nafiseh Vahed, Neda Kabiri, Reza Ali Akbari Khoei & Hanieh Salehi-Pourmehr. (2022) Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis. Journal of Breast Cancer 25:6, pages 454.
Crossref
Crossref
YuPeng Liu, Shu Zhao, YuXue Zhang, Justina Ucheojor Onwuka, QingYuan Zhang & XiaoDong Liu. (2021) Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies. Aging 13:15, pages 19835-19866.
Crossref
Crossref
Christopher Jackson, Alexandra L. J. Freeman, Zśofia Szlamka & David J. Spiegelhalter. (2021) The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis. PLOS ONE 16:2, pages e0246441.
Crossref
Crossref
Christopher N. George, Victor Canuas-Landero, Elizavet Theodoulou, Munitta Muthana, Caroline Wilson & Penelope Ottewell. (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology 25, pages 100317.
Crossref
Crossref
Philippe Clézardin, Sofia Sousa, Martine Croset, Francesco Pantano & Cyril Confavreux. 2020. Encyclopedia of Bone Biology. Encyclopedia of Bone Biology
403
420
.
Hadar Goldvaser & Eitan Amir. (2019) Role of Bisphosphonates in Breast Cancer Therapy. Current Treatment Options in Oncology 20:4.
Crossref
Crossref
Brent O'Carrigan, Matthew HF Wong, Melina L Willson, Martin R Stockler, Nick Pavlakis & Annabel Goodwin. (2017) Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews 2018:11.
Crossref
Crossref
Sukhbinder Dhesy-ThindGlenn G. FletcherPhillip S. BlanchetteMark J. ClemonsMelissa S. DillmonElizabeth S. FrankSonal GandhiRasna GuptaMihaela MatesBeverly MoyTed VandenbergCatherine H. Van Poznak. (2017) Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 35:18, pages 2062-2081.
Crossref
Crossref
James B. Elder, Ilya Laufer, Todd Vitaz & Mark Bilsky. 2017. Benzel's Spine Surgery, 2-Volume Set. Benzel's Spine Surgery, 2-Volume Set
985
1001.e5
.
Sabina Sangaletti, Claudio Tripodo, Alessandra Santangelo, Nadia Castioni, Paola Portararo, Alessandro Gulino, Laura Botti, Mariella Parenza, Barbara Cappetti, Rosaria Orlandi, Elda Tagliabue, Claudia Chiodoni & Mario P. Colombo. (2016) Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. Cell Reports 17:1, pages 233-248.
Crossref
Crossref
Guido Kranenburg, Jonas W. Bartstra, Maaike Weijmans, Pim A. de Jong, Willem P. Mali, Harald J. Verhaar, Frank L.J. Visseren & Wilko Spiering. (2016) Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis 252, pages 106-115.
Crossref
Crossref
P. Hadji, R.E. Coleman, C. Wilson, T.J. Powles, P. Clézardin, M. Aapro, L. Costa, J.-J. Body, C. Markopoulos, D. Santini, I. Diel, A. Di Leo, D. Cameron, D. Dodwell, I. Smith, M. Gnant, R. Gray, N. Harbeck, B. Thurlimann, M. Untch, J. Cortes, M. Martin, U.-S. Albert, P.-F. Conte, B. Ejlertsen, J. Bergh, M. Kaufmann & I. Holen. (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology 27:3, pages 379-390.
Crossref
Crossref
Heleen H. Van Acker, Sébastien Anguille, Yannick Willemen, Evelien L. Smits & Viggo F. Van Tendeloo. (2016) Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmacology & Therapeutics 158, pages 24-40.
Crossref
Crossref
Eva-Maria Fick, Alexander Katalinic & Annika Waldmann. (2015) The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany. Cancer Research and Treatment 47:4, pages 747-756.
Crossref
Crossref
. (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The Lancet 386:10001, pages 1353-1361.
Crossref
Crossref
Yupeng Liu, Chen Du, Yuxue Zhang, Shu Zhao, Lina Zhao, Pengfei Li, Fulan Hu, Lin Zhu, Yanlong Liu, Da Pang & Yashuang Zhao. (2015) Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials. BMJ Open 5:4, pages e007215.
Crossref
Crossref
M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, M. Knauer, M. Moik, R. Jakesz, M. Seifert, S. Taucher, V. Bjelic-Radisic, M. Balic, H. Eidtmann, W. Eiermann, G. Steger, W. Kwasny, P. Dubsky, U. Selim, F. Fitzal, G. Hochreiner, V. Wette, P. Sevelda, F. Ploner, R. Bartsch, C. Fesl & R. Greil. (2015) Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology 26:2, pages 313-320.
Crossref
Crossref
Richard Kremer, Bruno Gagnon, Ari N. Meguerditchian, Lyne Nadeau & Nancy Mayo. (2014) Effect of Oral Bisphosphonates for Osteoporosis on Development of Skeletal Metastases in Women With Breast Cancer: Results From a Pharmaco-Epidemiological Study. JNCI: Journal of the National Cancer Institute 106:11.
Crossref
Crossref
Naoki Hayashi, Ganiraju C. ManyamAna M. Gonzalez-AnguloNaoki Niikura, Hideko YamauchiSeigo Nakamura, Gabriel N. Hortobágyi, Keith A. BaggerlyNaoto T. Ueno. (2014) Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. The Oncologist 19:9, pages 909-914.
Crossref
Crossref
Robert Coleman, David Cameron, David Dodwell, Richard Bell, Caroline Wilson, Emma Rathbone, Maccon Keane, Miguel Gil, Roger Burkinshaw, Robert Grieve, Peter Barrett-Lee, Diana Ritchie, Victoria Liversedge, Samantha Hinsley & Helen Marshall. (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology 15:9, pages 997-1006.
Crossref
Crossref
Jamal Zekri, Maged Mansour & Syed Mustafa Karim. (2014) The anti-tumour effects of zoledronic acid. Journal of Bone Oncology 3:1, pages 25-35.
Crossref
Crossref
Ruta Rao. 2014. Breast Cancer. Breast Cancer
381
420
.
Alexander Paterson & Melissa Shea-Budgell. (2013) Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline. Journal of Clinical Medicine 2:4, pages 283-301.
Crossref
Crossref
Malgorzata Banys, Erich-Franz Solomayer, Gerhard Gebauer, Wolfgang Janni, Natalia Krawczyk, Hans-Joachim Lueck, Sven Becker, Jens Huober, Bernhard Kraemer, Birgit Wackwitz, Peter Hirnle, Diethelm Wallwiener & Tanja Fehm. (2013) Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 13:1.
Crossref
Crossref
Kent Russell, Eitan Amir, Alexander Paterson, Robert Josse, Christina Addison, Iryna Kuchuk & Mark Clemons. (2013) Does estrogen play a role in response to adjuvant bone-targeted therapies?. Journal of Bone Oncology 2:4, pages 167-173.
Crossref
Crossref
Naomi Gronich & Gad Rennert. (2013) Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates. Nature Reviews Clinical Oncology 10:11, pages 625-642.
Crossref
Crossref
Irit Ben-Aharon, Liat Vidal, Shulamith Rizel, Rinat Yerushalmi, Ofer Shpilberg, Aaron Sulkes & Salomon M. Stemmer. (2013) Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy—Effect on Survival: A Systematic Review and Meta-Analysis. PLoS ONE 8:8, pages e70044.
Crossref
Crossref
M.C. Winter & R.E. Coleman. (2013) Bisphosphonates in the Adjuvant Treatment of Breast Cancer. Clinical Oncology 25:2, pages 135-145.
Crossref
Crossref
Michael Poon, Liying Zhang, Florence Mok, Kenneth Li, Urban Emmenegger, Erin Wong, Michelle Zhou, Henry Lam, Nicholas Lao & Edward Chow. (2013) Adverse events across generations of bone-modifying agents in patients with solid tumor cancers reported in Phase III randomized trials. Journal of Comparative Effectiveness Research 2:1, pages 77-91.
Crossref
Crossref
Mehmet Ali Nahit Şendur, Sercan Aksoy, Şebnem Yaman, Zafer Arık, Nuriye Yıldırım Özdemir, Nurullah Zengin & Kadri Altundağ. (2012) Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Medical Oncology 29:4, pages 2601-2605.
Crossref
Crossref
Mark Clemons, Kent Russell, Luis Costa & Christina L. Addison. (2012) Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?. Breast Cancer Research and Treatment 134:2, pages 453-457.
Crossref
Crossref
Kent Russell, Mark Clemons, Luis Costa & Christina L. Addison. (2012) Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?. Journal of Bone Oncology 1:1, pages 12-17.
Crossref
Crossref
Matthew HF Wong, Martin R Stockler & Nick Pavlakis. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Camilo A. Molina, Ziya L. Gokaslan & Daniel M. Sciubba. (2012) Diagnosis and Management of Metastatic Cervical Spine Tumors. Orthopedic Clinics of North America 43:1, pages 75-87.
Crossref
Crossref
Michael Gnant, Peter Dubsky & Peyman Hadji. 2012. Prevention of Bone Metastases. Prevention of Bone Metastases
65
91
.
Robert E. Coleman, Helen Marshall, David Cameron, David Dodwell, Roger Burkinshaw, Maccon Keane, Miguel Gil, Stephen J. Houston, Robert J. Grieve, Peter J. Barrett-Lee, Diana Ritchie, Julia Pugh, Claire Gaunt, Una Rea, Jennifer Peterson, Claire Davies, Victoria Hiley, Walter Gregory & Richard Bell. (2011) Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine 365:15, pages 1396-1405.
Crossref
Crossref
C. Wilson & R.E. Coleman. (2011) Adjuvant therapy with bone-targeted agents. Current Opinion in Supportive & Palliative Care 5:3, pages 241-250.
Crossref
Crossref
Michael Gnant & Peyman Hadji. (2010) Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Research 12:6.
Crossref
Crossref
Tomifumi Onishi, Naoki Hayashi, Richard L. Theriault, Gabriel N. Hortobagyi & Naoto T. Ueno. (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nature Reviews Clinical Oncology 7:11, pages 641-651.
Crossref
Crossref
Heinz Jürgen Deuber & Friedrich Theiss. (2010) Bisphosphonate in der adjuvanten Therapie des MammakarzinomsBisphosphonates in Adjuvant Therapy of Breast Cancer. Medizinische Klinik 105:9, pages 635-646.
Crossref
Crossref
Michael Gnant. (2010) Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women?. Journal of Clinical Oncology 28:22, pages 3548-3551.
Crossref
Crossref
Rowan T. ChlebowskiZhao ChenJane A. CauleyGarnet AndersonRebecca J. RodaboughAnne McTiernanDorothy S. LaneJoAnn E. MansonLinda SnetselaarShagufta YasmeenMary Jo O'SullivanMonika SaffordSusan L. HendrixRobert B. Wallace. (2010) Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. Journal of Clinical Oncology 28:22, pages 3582-3590.
Crossref
Crossref
Lisanne L. Krens, Jara M. Baas, Hans Gelderblom & Henk-Jan Guchelaar. (2010) Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discovery Today 15:13-14, pages 502-516.
Crossref
Crossref
H.L. Neville-Webbe & R.E. Coleman. (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. European Journal of Cancer 46:7, pages 1211-1222.
Crossref
Crossref
Antonis Valachis, Nikolaos P. Polyzos, Vassilis Georgοulias, Dimitris Mavroudis & Davide Mauri. (2010) Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecologic Oncology 117:1, pages 139-145.
Crossref
Crossref
Matthew C Winter & Robert E Coleman. (2009) Bisphosphonates in breast cancer: teaching an old dog new tricks. Current Opinion in Oncology 21:6, pages 499-506.
Crossref
Crossref
Orit C. Freedman, Eitan Amir & Mark J. Clemons. (2009) Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?. Critical Reviews in Oncology/Hematology 72:1, pages 56-64.
Crossref
Crossref
Robert Coleman & Michael Gnant. (2009) New results from the use of bisphosphonates in cancer patients. Current Opinion in Supportive & Palliative Care 3:3, pages 213-218.
Crossref
Crossref
Davide Mauri, Antonis Valachis, Ilias P. Polyzos, Nikolaos P. Polyzos, Konstantinos Kamposioras & Lorenzo L. Pesce. (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis. Breast Cancer Research and Treatment 116:3, pages 433-439.
Crossref
Crossref
R.E. Coleman. (2009) Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy?. European Journal of Cancer 45:11, pages 1909-1915.
Crossref
Crossref
Martin Pecherstorfer. (2009) Treatment Options for Breast Cancer and Bone Metastases. Women's Health 5:2, pages 149-163.
Crossref
Crossref
Michael Gnant, Peter Dubsky, Florian Fitzal, Thomas Bachleitner-Hofmann, Ruth Exner, Peter Blaha, Raimund Jakesz, Walter Schippinger & Richard Greil. (2009) Bisphosphonates as adjuvant therapy for breast cancer. Current Breast Cancer Reports 1:1, pages 54-63.
Crossref
Crossref
Tim Van den Wyngaert, Manon T. Huizing, Eric Fossion & Jan B. Vermorken. (2009) Bisphosphonates in Oncology: Rising Stars or Fallen Heroes. The Oncologist 14:2, pages 181-191.
Crossref
Crossref